Multivariate analysis of parameters that affected overall survivors and acute leukemia evolution in patients with RA classified according to the FAB criteria
. | Overall survival . | . | Leukemic transformation . | . | ||
|---|---|---|---|---|---|---|
| Characteristic, by model . | Japanese HR (95% CI) . | German HR (95% CI) . | Japanese HR (95% CI) . | German HR (95% CI) . | ||
| Model A | ||||||
| Age older than 60 y | 5.1 (2.6-9.9)* | 2.2 (1.5-3.0)* | 1.6 (0.4-6.4) | 1.7 (0.9-3.3) | ||
| Sex, male | 1.2 (0.7-2.2) | 1.0 (0.8-1.4) | 1.6 (0.4-7.1) | 1.2 (0.7-2.1) | ||
| ANC fewer than 1.5 × 109/L | 1.2 (0.7-2.2) | 1.0 (0.7-1.3) | 2.0 (0.5-8.2) | 1.7 (0.9-3.1) | ||
| Platelet count fewer than 100 × 109/L | 1.3 (0.6-2.7) | 1.9 (1.4-2.5)* | 0.4 (0.1-1.9) | 2.2 (1.2-4.1)* | ||
| Hemoglobin concentration less than 100 g/L | 1.5 (0.8-2.8) | 1.8 (1.4-2.4)* | 1.0 (0.2-3.9) | 1.9 (1.1-3.5)* | ||
| Chromosome (IPSS), intermediate | 1.5 (0.6-3.6) | 1.1 (0.6-1.9) | 1.5 (0.2-14) | 2.3 (0.9-5.6) | ||
| Chromosome (IPSS), poor | 1.4 (0.5-4.2) | 2.8 (1.6-4.9)* | 11.9 (2.4-59)* | 6.6 (2.8-16)* | ||
| Model B | ||||||
| Age older than 60 y | 4.6 (2.5-8.7)* | 2.1 (1.5-2.9)* | 1.7 (0.5-6.3) | 1.6 (0.8-3.0) | ||
| Sex, male | 1.1 (0.6-2.0) | 1.2 (0.9-1.6) | 1.7 (0.4-6.7) | 1.2 (0.7-2.1) | ||
| IPSS, INT-1 | 1.0 (0.5-1.8) | 1.4 (1.0-2.0)* | 1.0 (0.2-4.7) | 3.1 (1.6-5.7)* | ||
| IPSS, INT-2 | 1.6 (0.5-4.7) | 4.0 (2.0-8.0)* | 8.6 (1.7-43)* | 9.5 (3.2-27)* | ||
. | Overall survival . | . | Leukemic transformation . | . | ||
|---|---|---|---|---|---|---|
| Characteristic, by model . | Japanese HR (95% CI) . | German HR (95% CI) . | Japanese HR (95% CI) . | German HR (95% CI) . | ||
| Model A | ||||||
| Age older than 60 y | 5.1 (2.6-9.9)* | 2.2 (1.5-3.0)* | 1.6 (0.4-6.4) | 1.7 (0.9-3.3) | ||
| Sex, male | 1.2 (0.7-2.2) | 1.0 (0.8-1.4) | 1.6 (0.4-7.1) | 1.2 (0.7-2.1) | ||
| ANC fewer than 1.5 × 109/L | 1.2 (0.7-2.2) | 1.0 (0.7-1.3) | 2.0 (0.5-8.2) | 1.7 (0.9-3.1) | ||
| Platelet count fewer than 100 × 109/L | 1.3 (0.6-2.7) | 1.9 (1.4-2.5)* | 0.4 (0.1-1.9) | 2.2 (1.2-4.1)* | ||
| Hemoglobin concentration less than 100 g/L | 1.5 (0.8-2.8) | 1.8 (1.4-2.4)* | 1.0 (0.2-3.9) | 1.9 (1.1-3.5)* | ||
| Chromosome (IPSS), intermediate | 1.5 (0.6-3.6) | 1.1 (0.6-1.9) | 1.5 (0.2-14) | 2.3 (0.9-5.6) | ||
| Chromosome (IPSS), poor | 1.4 (0.5-4.2) | 2.8 (1.6-4.9)* | 11.9 (2.4-59)* | 6.6 (2.8-16)* | ||
| Model B | ||||||
| Age older than 60 y | 4.6 (2.5-8.7)* | 2.1 (1.5-2.9)* | 1.7 (0.5-6.3) | 1.6 (0.8-3.0) | ||
| Sex, male | 1.1 (0.6-2.0) | 1.2 (0.9-1.6) | 1.7 (0.4-6.7) | 1.2 (0.7-2.1) | ||
| IPSS, INT-1 | 1.0 (0.5-1.8) | 1.4 (1.0-2.0)* | 1.0 (0.2-4.7) | 3.1 (1.6-5.7)* | ||
| IPSS, INT-2 | 1.6 (0.5-4.7) | 4.0 (2.0-8.0)* | 8.6 (1.7-43)* | 9.5 (3.2-27)* | ||
Model A included age category, sex, dichotomized peripheral blood counts, and chromosome category of IPSS. Model B included age category, sex, and IPSS score.
HR indicates hazard ratio; 95% CI, 95% confidence interval; ANC, absolute neutrophil count; IPSS, International Prognosis Score System; INT-1, Intermediate-1; INT-2, intermediate-2.
Statistically significant hazard ratio.